Nemus Bioscience Inc (OTCMKTS:NMUS – Get Free Report) dropped 9.5% on Tuesday . The company traded as low as $0.60 and last traded at $0.65. Approximately 1,004,500 shares changed hands during mid-day trading, an increase of 166% from the average daily volume of 377,395 shares. The stock had previously closed at $0.72.
Nemus Bioscience Stock Down 9.5 %
The business has a 50 day moving average price of $8.94 and a two-hundred day moving average price of $5.02.
About Nemus Bioscience
Nemus Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus.
Further Reading
- Five stocks we like better than Nemus Bioscience
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Insider-Buy Stocks to Add to Your Watchlist Now
- What is the S&P 500 and How It is Distinct from Other Indexes
- Commvault Stock: AI Cybersecurity Giant Ready to Double Again
- What is a SEC Filing?
- Intuit Stock Ready to Soar: RBC Sees Big Upside with GenAI
Receive News & Ratings for Nemus Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemus Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
